LANCASTER, Calif. / May 22, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in Minneapolis, MN. Mr. O’Connor will host one-on-one and small group meetings throughout the day.
Each year, Craig-Hallum hosts a multi-industry investor conference featuring more than 130 public companies where institutional clients can meet formally with corporate management. Attendance is by invitation only. For more information about the conference, please visit the Craig-Hallum conference website.
About Simulations Plus
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
Last Trade: | US$28.58 |
Daily Change: | -0.30 -1.04 |
Daily Volume: | 342,168 |
Market Cap: | US$573.600M |
August 23, 2024 August 01, 2024 July 30, 2024 July 11, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB